Navigation Links
Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
Date:6/11/2008

TOKYO and NEW DELHI, India, June 11 /PRNewswire/ -- Daiichi Sankyo Company, Limited (TSE: 4568.JP) ("Daiichi Sankyo"), one of the largest pharmaceutical companies in Japan, and Ranbaxy Laboratories Limited (NSE/BSE: Ranbaxy/500359) ("Ranbaxy"), among the top 10 generic companies in the world and India's largest pharmaceutical company, announced on June 11 that a binding Share Purchase and Share Subscription Agreement (the "SPSSA") was entered into between Daiichi Sankyo, Ranbaxy and the Singh family, the largest and controlling shareholders of Ranbaxy (the "Sellers"). Pursuant to the Agreement, Daiichi Sankyo will acquire the entire shareholding of the Sellers in Ranbaxy and further seek to acquire the majority of the voting capital of Ranbaxy at a price of Rs737 per share with the total transaction value expected to be between US$3.4 to US$4.6 billion (currency exchange rate: US$1=Rs43). On the post-closing basis, the transaction would value Ranbaxy at US$8.5 billion.

For more details, please check full text of the press release from Daiichi Sankyo website: http://www.daiichisankyo.com/

Contact:

Motomi Takahashi (for Daiichi Sankyo)

Dentsu Public Relations Inc.

Phone: +81-3-5565-8434

E-mail: m-takahashi@dentsu-pr.co.jp

Ramesh L. Adige (for Ranbaxy)

Executive Director- Corporate Affairs and Global Corporate Communications

Ranbaxy Laboratories Limited

Phone: +91-124-4135000

E-mail: ramesh.adige@ranbaxy.com


'/>"/>
SOURCE Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
2. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
3. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
4. Ranbaxy Receives Tentative Approval For Valsartan Tablets
5. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
6. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
7. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
8. Naked Juice Brings Consumers Happiness by the Billions With First 100% Juice Smoothie Containing Probiotics
9. Vitamin Relief Brings Needed Nutrition to School District Resurrecting After Katrina
10. Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During America on the Move Week With the YMCA, September 22-29, 2007
11. PSI Brings its Pioneering Efforts to a Close
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... ... San Diego physician and surgeon Dr. James Veltmeyer, author of the Medical ... the 52nd Congressional District currently held by Representative Scott Peters. , “I have ... age eleven after suffering homelessness and hardship in a distant land, I don’t just ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... The ... Excellence Awards (IDSA IDEA®) 2017 Ceremony and Gala on Aug. 19, 2017 in ... one of the world’s most prestigious and rigorous design competitions. See all the winners ...
(Date:8/20/2017)... ... August 20, 2017 , ... ... Compliance Management System has assisted multiple clients in successfully passing audits such ... Organization Control Level 2 (AICPA SOC Level 2), and State Data Use Agreement ...
(Date:8/20/2017)... ... 20, 2017 , ... Are you an adult with gluten intolerance or Celiac ... be interested in participating in a research study that focuses on family interactions when ... about the relational aspects of adults who have gluten sensitivities who cohabitate with other ...
(Date:8/19/2017)... ... ... Western University of Health Sciences will host a special symposium and exhibition about ... on Wednesday, September 6, 2017. , The symposium will be from noon to 1 ... from 1 to 3 p.m. showcasing virtual reality education technology, high speed 3-D printing ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., ... , today announced that the company has provided ... University of North Carolina at Chapel Hill and to ... designed to characterize and quantify HIV reservoir and viral ... pharmacological intervention. The HIV Cure Center is a joint ...
(Date:8/11/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it will release its second ... a conference call at 9:00am ET. The Company will ... and its strategy and outlook for the remainder of ... Raphael , Chief Executive Officer, and Zvi Ben-David ...
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
Breaking Medicine Technology: